Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Item

http://www.wikidata.org/entity/Q34437074

Q34437074

about

Light chain (AL) amyloidosis: update on diagnosis and management Mechanism of action of lenalidomide in hematological malignancies Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma Appraisal of immunoglobulin free light chain as a marker of response The Prevalence and Management of Systemic Amyloidosis in Western Countries Update on treatment of light chain amyloidosis Amyloid diseases of the heart: current and future therapies Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosi Implantable cardioverter defibrillators in patients with cardiac amyloidosis.A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis.An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis.Flow cytometry-based immunophenotypic analysis of primary systemic light chain amyloidosis.Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study.Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue.A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma Regression of cardiac amyloidosis following stem cell transplantation: a comparison between echocardiography and cardiac magnetic resonance imaging in long-term survivors.First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction Myocardial Deformation in Cardiac Amyloid Light-chain Amyloidosis: Assessed with 3T Cardiovascular Magnetic Resonance Feature Tracking.Thoracic amyloidomas: Two case reports of an evasive diagnosis Radioimmunodetection of amyloid deposits in patients with AL amyloidosis.Guideline of transthyretin-related hereditary amyloidosis for clinicians.Senile systemic amyloidosis: clinical features at presentation and outcome.Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.Systemic AA amyloidosis: epidemiology, diagnosis, and management.Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.Impact of regional left ventricular function on outcome for patients with AL amyloidosis.The evolving use of serum free light chain assays in haematology.Predictive value of assessing diastolic strain rate on survival in cardiac amyloidosis patients with preserved ejection fraction.Amyloidosis of the renal pelvis: a harbinger of mammary carcinoma?Kidney dysfunction during lenalidomide treatment for AL amyloidosis.Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial Amyloidosis: pathogenesis and new therapeutic options.The amyloidogenic V122I transthyretin variant in elderly black Americans.Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis

P2860

Q21198863-C5E5778B-219D-4BFE-B4ED-C0EAAB7A218B Q21198872-A5BECDC3-2786-407D-BA85-599475FA4B61 Q21285161-009C53E8-BDAA-45DE-AADA-C0470FE8A23A Q24624398-A3DAE4EF-747A-4383-AFD9-29EE5AE2A654 Q26740436-31A67410-BD65-43CB-BDBE-DE02C4118B9C Q26829735-B03ECB9A-1973-4C44-8058-E9AA058FE171 Q27023836-8106C656-3C44-4BBF-9C9C-E61D862FBDF8 Q30278687-2A987830-CBC6-47BA-9017-01A2D6E36F90 Q30469018-26B3A43F-CCD6-4CCB-B196-992F0A02C199 Q33162514-D9E01B2B-21F7-4D8E-8F40-E65747B1E990 Q33165133-2E1A0588-3105-426A-9C8A-648A1D4B4633 Q33304297-AF4EBDE3-D830-40CA-BCD7-B40DBFE8A954 Q33417805-3450E25A-5534-4BA6-801F-FF074D656E7D Q33427726-14F0B2E3-D4C8-4A15-BE9F-23E58A5300DA Q33598391-B0AF58FE-FFA5-49D3-AB45-7FC27921A86E Q33698796-36F66A3D-7275-4441-9BBE-EE60EC364953 Q33715284-01E3A3DE-BE8E-4417-A8B2-8B995AD2A8EE Q33718805-5D5EB36A-3330-4417-84B0-A0DEC3325978 Q33744195-601E64C9-AB14-449E-A076-566319C61D10 Q33753528-F7080FE1-656A-43FE-89C1-E525B4BC2791 Q33795363-46CE3CF7-941F-4EEB-AA78-FA254F57C661 Q33812497-DAAE9DEE-64E9-4299-9766-831F6C42E541 Q33908070-770D3DCF-255A-4FED-A0D2-960CA1F6F3AB Q34193315-2261B58B-7540-4FE5-945E-491D796702D3 Q34328734-B81D50BC-10A6-47E8-B33E-0914303ED5AD Q34340740-2A99EFAF-0675-451F-BE65-5EC6E8916A60 Q34353682-188867C8-773A-488E-BB91-13D11DED4CB9 Q34446219-DD8B647E-4444-414D-83AE-9A878998C34B Q34450428-16F357B2-2C1A-41DA-A250-0F408ECCE2DC Q34450910-785834D8-2140-42E0-AD49-08964620CCB0 Q34631654-0FF7C31E-6E68-494D-85C4-B531165687D8 Q34758218-3F96DD64-CD9F-45B9-B853-FA34D51A3162 Q34776977-BE64CF64-94E9-4559-A62A-5C5AFCE12C70 Q35015764-EF33E664-5E84-489C-A664-15A86371BF9B Q35025410-3634D421-7112-4ED2-9983-D1C266CB3A4A Q35067588-CBD41CB6-FF05-4AD0-A98A-80A2CCFA0700 Q35081363-FC39A1EB-5688-4480-86D6-4C7DB513A18D Q35111771-14D30EAE-16D6-4B47-928B-4115BF136577 Q35242225-3BEE91FC-D9BE-4B19-BF6B-8C808777106D Q35244195-CA0AF2AF-2F49-4BAE-B141-4C7A73CE1EBD

P2860

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Item

http://www.wikidata.org/entity/Q34437074

description

2005 nî lūn-bûn

@nan

2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu